Several vaccine viruses (e. g. human influenza virus) are produced in the cavity of embryonated hens' eggs or in primary chicken fibroblast. By using eggs as a cell substrate for virus propagation, the risk of allergic reactions against egg-derived proteins, costs and complicated logistics, dangers of an essentially open production system and lot variations have to be considered. Our designed avian cell lines AGE1.CR® and AGE1.CR.pIX® allow scalable chemically defined vaccine manufacturing to overcome limitations of egg-based production and to increase industrial flexibility.
For detailed information please see:
A chemically defined production process for highly attenuated poxviruses.
Jordan I, Northoff S, Thiele M, Hartmann S, Horn D, Höwing K, Bernhardt H, Oehmke S, von Horsten H, Rebeski D, Hinrichsen L, Zelnik V, Mueller W, Sandig V.
Biologicals (2011) 39:50-58.
An avian cell line designed for production of highly attenuated viruses.
Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V.
Vaccine (2009) 27:748-756.